Kairos Pharma Files 10-K/A Amendment for FY24 Report

TL;DR

**KAPA's 10-K/A signals potential financial restatements for 2024, demanding immediate investor scrutiny for hidden risks or opportunities.**

AI Summary

Kairos Pharma, LTD. (KAPA) filed a 10-K/A Amendment No. 2 for the fiscal year ended December 31, 2024, indicating corrections or updates to its previously filed annual report. As a smaller reporting company and an emerging growth company, KAPA operates under specific regulatory allowances, such as potentially extended transition periods for new accounting standards. The filing confirms KAPA has met all Section 13 or 15(d) reporting requirements for the preceding 12 months and has submitted all required Interactive Data Files. While specific financial figures for revenue and net income are not detailed in the provided excerpt, the amendment itself suggests a need to clarify or correct previously reported financial or operational data. Key business changes or strategic outlooks are not explicitly stated in this amendment's introductory section, but the nature of a 10-K/A often relates to restatements of financial results, changes in accounting principles, or updates to risk factors. The company's common stock is traded on the NYSE American under the symbol KAPA, highlighting its public market presence and regulatory obligations. The amendment's focus is on ensuring compliance and accuracy of its annual disclosures for the 2024 fiscal year.

Why It Matters

This 10-K/A filing by Kairos Pharma, LTD. is crucial for investors as it signals potential material changes or corrections to the company's previously reported financial statements or disclosures for fiscal year 2024. Such amendments can impact investor confidence, stock valuation, and the perceived reliability of management's reporting. For employees and customers, while less direct, financial restatements can sometimes reflect underlying operational or strategic issues. In the competitive pharmaceutical sector, transparency and accurate reporting are paramount, and any significant amendments could draw scrutiny from competitors and regulators, potentially affecting KAPA's market standing.

Risk Assessment

Risk Level: medium — The filing of a 10-K/A, especially Amendment No. 2, indicates that Kairos Pharma, LTD. is correcting or updating previously reported annual financial information for the fiscal year ended December 31, 2024. This inherently carries a medium risk as it suggests potential inaccuracies in prior disclosures, which could range from minor clerical errors to significant financial restatements impacting revenue, net income, or balance sheet items. The lack of specific details in the excerpt about the nature of the amendment prevents a 'high' risk assessment, but any amendment to an annual report warrants careful review.

Analyst Insight

Investors should immediately review the full 10-K/A filing to understand the specific changes and their impact on Kairos Pharma's financial health and future prospects. Pay close attention to any restated financial figures, changes in accounting policies, or updated risk factors, as these could materially alter the investment thesis for KAPA.

Key Numbers

• 2024-12-31 — Fiscal Year End (The period covered by the amended annual report.)
• 2025-07-28 — Filing Date (Date the 10-K/A Amendment No. 2 was filed.)
• $0.001 — Par Value per Share (The stated par value of Kairos Pharma's common stock.)
• 2 — Amendment Number (This is the second amendment to the 10-K for the fiscal year 2024.)

Key Players & Entities

• Kairos Pharma, LTD. (company) — registrant filing the 10-K/A
• SEC (regulator) — recipient of the 10-K/A filing
• NYSE American (company) — exchange where KAPA common stock is registered
• $0.001 (dollar_amount) — par value per share of common stock
• December 31, 2024 (date) — fiscal year end for the report
• July 28, 2025 (date) — filing date of the 10-K/A
• 001-42275 (regulator) — Commission file number
• 46-2993314 (company) — IRS Employer Identification No. for Kairos Pharma, LTD.

FAQ

Industry Context

Kairos Pharma operates within the Pharmaceutical Preparations industry (SIC 2834). This sector is characterized by high research and development costs, stringent regulatory oversight from bodies like the FDA, and a competitive landscape driven by innovation and patent protection. Companies in this space often focus on developing novel therapeutics, generics, or specialized drug formulations.

Regulatory Implications

As a publicly traded company on the NYSE American and a smaller reporting/emerging growth company, Kairos Pharma is subject to SEC reporting requirements. The filing of a 10-K/A indicates a commitment to accurate disclosure, but the need for amendment suggests potential areas of scrutiny or past inaccuracies that investors should monitor.

What Investors Should Do

1. Review the specific details of Amendment No. 2.
2. Monitor future filings for consistency and accuracy.
3. Assess the impact of 'smaller reporting company' and 'emerging growth company' status.

Key Dates

• 2024-12-31: Fiscal Year End — This is the end date for the reporting period covered by the 10-K/A Amendment No. 2.
• 2025-07-28: Filing Date of 10-K/A Amendment No. 2 — Indicates the date the company submitted its amended annual report, suggesting updates or corrections to previously filed information.

Glossary

10-K/A

An amended annual report filed with the SEC, used to correct or update previously filed Form 10-K information. (This filing is an amendment to Kairos Pharma's annual report, indicating a need for correction or clarification of its financial or operational disclosures.)

Smaller Reporting Company

A company that meets certain SEC criteria for revenue, public float, and market capitalization, allowing for scaled disclosure requirements. (Kairos Pharma qualifies as a smaller reporting company, which may affect the extent and complexity of its SEC filings.)

Emerging Growth Company

A company that has total annual gross revenues of less than $1.235 billion during its most recently completed fiscal year and meets other criteria, allowing for extended transition periods for new accounting standards. (As an emerging growth company, Kairos Pharma may benefit from delayed adoption of certain new accounting standards, impacting its financial reporting timeline.)

NYSE American

A stock exchange operated by NYSE Group, Inc., which lists smaller companies compared to the New York Stock Exchange. (Kairos Pharma's common stock is traded on the NYSE American, indicating its public market status and adherence to exchange listing requirements.)

Section 13 or 15(d) reporting requirements

These sections of the Securities Exchange Act of 1934 mandate that public companies file regular reports (like 10-K, 10-Q, 8-K) with the SEC to provide ongoing disclosure to investors. (The filing confirms Kairos Pharma has met these requirements for the preceding 12 months, demonstrating ongoing compliance with federal securities laws.)

Interactive Data File

Electronic data files, typically in XBRL format, that tag financial information in SEC filings, making it easier for investors and analysts to analyze. (Kairos Pharma has submitted all required Interactive Data Files, ensuring its financial data is accessible and machine-readable.)

Year-Over-Year Comparison

As this is an amendment to the 2024 10-K, a direct comparison of key metrics to the previous year's full 10-K is not possible from this excerpt. However, the amendment itself implies that the previously reported data for fiscal year 2024 may require adjustment. The filing confirms compliance with reporting requirements for the preceding 12 months, but the nature of the amendment suggests a need to re-evaluate the accuracy of that reported data.

Filing Details

This Form 10-K/A (Form 10-K/A) was filed with the SEC on July 28, 2025 regarding Kairos Pharma, LTD. (KAPA).

View full filing on EDGAR

View Full Filing

View this 10-K/A filing on SEC EDGAR